Company Profile

MacuLogix Inc (AKA: Apeliotus Vision Science, Inc.~Apeliotus Technologies Inc)
Profile last edited on: 10/28/22      CAGE: 3UEX5      UEI:

Business Identifier: Early detection and tracking of age-related macular degeneration (AMD)
Year Founded
2004
First Award
2005
Latest Award
2009
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1214 Research Boulevard
Hummelstown, PA 17036
   (717) 583-1220
   info@maculogix.com
   www.maculogix.com
Location: Single
Congr. District: 10
County: Dauphin

Public Profile

Formerly known as Apeliotus Technologies Inc, Maculogix Inc is a pharmaceutical company developing tools for early detection. tracking and diagnosis of retinal diseases, particularly age-related macular degeneration (AMD), a cause of blindness. The Company’s AdaptDx® is the first practical measurement tool for dark adaptation - the transition from being light-adapted to being dark-adapted.- and known to be substantially impaired in degenerative diseases of the macula such as age-related macular degeneration (AMD) and inherited macular dystrophies. MacuLogix’ AdaptDx™ has received FDA 510(k) clearance for measurement of dark adaptation function and patient testing has been completed to support validation as a diagnostic for AMD. In use by a number of pharmaceutical companies, AdaptDx™ is not currently cleared for sale as a diagnostic. AdaptDx™ is also involved in the development of drugs for early AMD. Based on significant technical advances, the AdaptDx provides doctors with an easy-to-use functional test similar to routine perimetry testing for glaucoma. AdaptDX is designed to function as a screening tool to enable doctors to identify individuals at the earliest stages of AMD and track the disease for treatment and is being used by a number of pharmaceutical companies in the development of drugs for early AMD The firm's AdaptDx™ has received FDA 510(k) clearance for measurement of dark adaptation function and patient testing has been completed to support validation as a diagnostic for AMD. However, to date (April 2017) the AdaptDx™ is not currently cleared for sale as

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
50-74
Revenue Range
5M-7.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
20-24

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2009 1 NIH $142,558
Project Title: Adaptrx: Surrogate Marker For Vision Loss In Amd
2008 2 NIH $1,218,985
Project Title: Diagnostic for Age-Related Macular Degeneration
2007 1 NIH $139,832
Project Title: Topical Treatment for Mild Psoriasis
2006 1 NIH $189,146
Project Title: Polymer Stentgraft for Treatment of Cerebral Aneurysms

Key People / Management

  John G Edwards -- CEO

  Wendy B Bollag

  William H Grace -- VP Engineering

  Gregory R Jackson -- Founder, CtO & Associate Professor at Penn State

  Gary L Loomis

  Joan W Miller -- Clinical Advisor

  Edward R Newill -- VP Sales and Marketing

  James V Pietropaolo -- COO

Company News